Why compare them?
These records are compared to clarify how their mechanisms, research areas, and evidence maturity differ.
Simple first. Deeper when you want it.
Understand the differences that matter.
See the biggest similarities, differences, strengths, limitations, and unanswered questions first—then open the evidence behind them.
Compound comparison
Thymosin Alpha-1 vs. Cagrilintide
Understand the meaningful overlap, differences, evidence, and unknowns—then go deeper only when you want to.
60-Second Summary
The answer first
Current evidenceComparable evidence base
No direct head-to-head study is represented. This comparison uses separate evidence records that may differ in population, duration, route, dose, and endpoint.
✓ Shared
Shared Similarities
- Both have controlled human research, although the questions and designs may differ.
⇄ Different
Biggest Difference
Thymosin Alpha-1 is distinguished by a thymic immune-modulating peptide with substantial disease-specific human research—but the largest modern Phase 3 trial was negative, and general immune-boosting claims remain unproven; Cagrilintide is distinguished by long-acting amylin analogue with amylin- and calcitonin-receptor activity; it is not a GLP-1 receptor agonist and is not the same evidence record as CagriSema.
? Unknown
Biggest Unknown
No direct head-to-head study establishes how these compounds compare under the same population, dose, duration, and endpoints.
Key Takeaways
Thymosin Alpha-1 is distinguished in the current record by a thymic immune-modulating peptide with substantial disease-specific human research—but the largest modern Phase 3 trial was negative, and general immune-boosting claims remain unproven. Cagrilintide is distinguished by long-acting amylin analogue with amylin- and calcitonin-receptor activity; it is not a GLP-1 receptor agonist and is not the same evidence record as CagriSema. Neither is objectively “better”; the useful question is which evidence record addresses the research question being asked.
Research matrix
Which question has stronger current support?
Research questionStronger current supportExplanation
Human evidenceThymosin Alpha-1
Thymosin Alpha-1: Mixed human evidence. Cagrilintide: Developing human evidence.
Regulatory historyComparable
Thymosin Alpha-1: Not FDA approved. Cagrilintide: Investigational — Phase 3.
Mechanistic breadthComparable
More named targets describes mechanistic breadth; it does not establish greater effectiveness.
Direct comparisonUnknown
Separate studies cannot establish comparative superiority.
Deeper when you want it
Explore the evidence and nuance
Best-studied areas and pathway mapSee shared targets, unique pathways, and the research questions attached to each record.
Thymosin Alpha-1
- Sepsis and severe-infection outcomes
- Chronic hepatitis B
- COVID-19 add-on treatment
- Cancer-treatment adjunct research
Cagrilintide
- Weight management
- Appetite and energy intake
- Obesity with type 2 diabetes
- Visceral and ectopic fat
Pathway and research map
Shared foundation and unique questions
Research confidence by questionCompare regulatory, human-evidence, outcome, and administration records side by side.
Question by question
What each evidence base can actually answer
Regulatory statusEvidence, not a winner
Thymosin Alpha-1Not FDA approved
Not FDA approved. FDA identifies possible immunogenicity, peptide-related impurities, API-characterization complexity, and inadequate safety information for compounded TA1.
CagrilintideInvestigational
Investigational. No FDA-approved standalone cagrilintide product, consumer dose, reconstitution method, or official storage procedure.
Evidence depthEvidence, not a winner
Thymosin Alpha-1Multiple controlled studies
Multiple controlled studies across sepsis, viral hepatitis, COVID-19, and oncology, plus mechanistic research and active registered cancer trials.
CagrilintidePhase 2 + Phase 3 pending
One published 706-participant Phase 2 monotherapy trial, a 105-participant thorough-QT study, sponsor-reported Phase 3 component-arm data, and two active dedicated Phase 3 RENEW trials without posted results.
Weight outcomesEvidence, not a winner
Thymosin Alpha-1No dedicated evidence
No dedicated controlled human weight-management or body-composition evidence was located.
CagrilintidePeer-reviewed Phase 2
Phase 2 reported mean reductions of 6.0% to 10.8% across studied cagrilintide arms versus 3.0% placebo at 26 weeks. A sponsor-reported Phase 3 component arm later reported 11.8% versus 2.3% at 68 weeks under an efficacy estimand.
Type 2 diabetesEvidence, not a winner
Thymosin Alpha-1No dedicated benefit evidence
No dedicated diabetes-treatment evidence. A sepsis subgroup signal by diabetes status requires confirmation and is not diabetes-efficacy evidence.
CagrilintidePhase 3 registered
RENEW 2 is studying standalone cagrilintide in adults with overweight or obesity and type 2 diabetes; no results were posted by the cutoff.
Obstructive sleep apnoeaEvidence, not a winner
Thymosin Alpha-1No dedicated evidence
No dedicated controlled human obstructive-sleep-apnoea evidence was located.
CagrilintideNo dedicated evidence
No dedicated completed controlled human obstructive-sleep-apnoea outcome study was located.
Cardiovascular outcomesEvidence, not a winner
Thymosin Alpha-1No dedicated outcome evidence
No dedicated cardiovascular-outcome program was located; disease-specific infection and oncology trials do not establish cardiovascular benefit.
CagrilintideQT study only
A 105-participant thorough-QT study found no clinically relevant QTc prolongation at the tested exposure. That narrow result is not a cardiovascular outcomes trial.
Administration and handlingEvidence, not a winner
Thymosin Alpha-1Disease-specific trial protocols
Published protocols were disease- and formulation-specific subcutaneous regimens. They describe monitored trials, not general dosing or self-administration guidance.
CagrilintideTrial descriptions only
Published and registered studies describe once-weekly subcutaneous administration under protocol-specific escalation. These are trial descriptions, not approved dosing instructions.
Comparison limitationsUnderstand what this comparison cannot establish before interpreting separate studies.
Comparable evidence base
- No direct head-to-head trial is represented for this pair.
- Separate studies may use different populations, endpoints, durations, doses, routes, and estimands.
- Results should not be interpreted as comparative superiority or individual guidance.
Current unknowns
Questions the evidence cannot answer yet
- Whether any biomarker-defined subgroup has reproducible benefit, long-term repeated-use safety, and whether broad wellness claims translate into meaningful outcomes.
- Whether the dedicated RENEW Phase 3 trials confirm long-term standalone efficacy and safety in people with and without type 2 diabetes.
Community Intelligence
Emerging patterns, clearly separated from evidence
Thymosin Alpha-1
No community experiences yetBe the first account holder to contribute.
Cagrilintide
No community experiences yetBe the first account holder to contribute.
Community Intelligence summarizes structured, self-reported experiences. It can reveal patterns and useful research questions, but it cannot prove safety, effectiveness, or cause and effect. Published evidence is always shown separately.